Products Categories
| CAS No.: | 98319-26-7 |
|---|---|
| Name: | Finasteride |
| Molecular Structure: | |
|
|
|
| Formula: | C23H36N2O2 |
| Molecular Weight: | 372.551 |
| Synonyms: | Proscar (TN);Finasteride (USP);Finpecia;4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)-;Proscar;Finastid;Propecia (TN);Propecia;MK-0906;MK 906;Finasteride [USAN:BAN:INN];MK-906;Prostide;Chibro-Proscar;Finasterida [INN-Spanish];Finasteridum [INN-Latin];N-tert-butyl-4-aza-5alpha-androsta-3-oxo-17beta-carboxamide;Finasteride 99%; |
| EINECS: | 620-534-3 |
| Density: | 1.065 g/cm3 |
| Melting Point: | 253 °C |
| Boiling Point: | 576.6 °C at 760 mmHg |
| Flash Point: | 177.4 °C |
| Solubility: | DMSO: 32 mg/mL, soluble; insoluble in water |
| Appearance: | white to off-white crystalline powder |
| Hazard Symbols: |
 Xn, T, Xi
|
| Risk Codes: | 22-61-60-36/37/38 |
| Safety: | 36/37/39-45-53-36-26 |
| PSA: | 58.20000 |
| LogP: | 4.53420 |
What can I do for you?
Get Best Price
1. Introduction of Finasteride
Finasteride, with the IUPAC Name of (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-Butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide, is one kind of white crystalline powder. Its classification code are Drug / Therapeutic Agent; Enzyme inhibitors; Inhibitor [alpha reductase] and Reproductive Effect. This chemical belongs to the Product Categories which include Active Pharmaceutical Ingredients; API; Biochemistry; Steroids; Steroids (Others); Intermediates & Fine Chemicals; Pharmaceuticals; Vitamin Ingredients; Intracellular receptor.
2. Properties of Finasteride
Finasteride has the following datas: (1)Index of Refraction: 1.523; (2)Molar Refractivity: 106.9 cm3; (3)Molar Volume: 349.5 cm3; (4)Density: 1.065 g/cm3; (5)Flash Point: 177.4 °C; (6)Melting point: 253 °C; (7)Surface Tension: 37.7 dyne/cm; (8)Water solubility: insoluble; (9)Solubility: DMSO: 32 mg/mL, soluble; (10)Enthalpy of Vaporization: 86.34 kJ/mol; (11)Boiling Point: 576.6 °C at 760 mmHg; (12)Vapour Pressure: 2.69E-13 mmHg at 25 °C.
3. Structure Descriptors of Finasteride
You could convert the following datas into the molecular structure:
(1).Canonical SMILES: CC12CCC3C(C1CCC2C(=O)NC(C)(C)C)CCC4C3(C=CC(=O)N4)C
(2).Isomeric SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C
(3).InChI: InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1
(4).InChIKey: DBEPLOCGEIEOCV-WSBQPABSSA-N
4. Toxicity of Finasteride
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD50 | oral | > 1gm/kg (1000mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING | Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994. |
| mouse | LD50 | intraperitoneal | 372mg/kg (372mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994. |
| mouse | LD50 | oral | 486mg/kg (486mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994. |
| mouse | LD50 | subcutaneous | > 2gm/kg (2000mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994. | |
| rat | LD50 | intraperitoneal | 885mg/kg (885mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) GASTROINTESTINAL: ULCERATION OR BLEEDING FROM SMALL INTESTINE GASTROINTESTINAL: PERITONITIS | Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994. |
| rat | LD50 | oral | 418mg/kg (418mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) GASTROINTESTINAL: ULCERATION OR BLEEDING FROM STOMACH LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994. |
| rat | LD50 | subcutaneous | > 2gm/kg (2000mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994. |
Xn,
T,
Xi 6. Use of Finasteride
Finasteride (CAS NO.98319-26-7) is used as a treatment in benign prostatic hyperplasia (BPH) in low doses, and prostate cancer in higher doses. A May, 2008 study indicates that finasteride reduces the rate of prostate cancer by 30%. It is also indicated for use in combination with doxazosin therapy to reduce the risk for symptomatic progression of BPH. Additionally, it is registered in many countries for androgenetic alopecia (male-pattern baldness).
